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Abstract 
A novel, efficient delivery system for iron (Fe2+) was developed using the alginate biopolymer. 
Iron loaded alginate nanoparticles were synthesized by a controlled ionic gelation method and was 
characterized with respect to particle size, zeta potential, morphology and encapsulation 
efficiency. Successful loading was confirmed with Fourier Transform Infrared spectroscopy and 
Thermogravimetric Analysis. Electron energy loss spectroscopy study corroborated the loading of 
ferrous into the alginate nanoparticles. Iron encapsulation (70%) was optimized at 0.06% Fe (w/v) 
leading to the formation of iron loaded alginate nanoparticles with a size range of 15-30 nm and 
with a negative zeta potential (-38 mV). The in vitro release studies showed a prolonged release 
profile for 96 h. Release of iron was around 65-70% at pH of 6 and 7.4 whereas it was less than 
20% at pH 2. The initial burst release upto 8 h followed zero order kinetics at all three pH values. 
All the release profiles beyond 8 h best fitted the Korsmeyer-Peppas model of diffusion. Non 
Fickian diffusion was observed at pH 6 and 7.4 while at pH 2 Fickian diffusion was observed.    
Keywords: Anemia, ferrous sulfate, alginate nanoparticles, iron loaded nanocomposite, 
bioavailability  
 
Chemical compounds studied in this article 
Sodium alginate (PubChem CID: 5102882); Ferrous sulphate (PubChem CID: 24393); Calcium 
chloride (PubChem CID: 5284359; Sorbitan monooleate (PubChem CID: 9920342); L-Ascorbic 
acid (PubChem CID: 54670067)
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1. Introduction 1 
Iron deficiency has become the most common nutritional deficiency today (Horton & Ross, 2 
2003).Since the body requires iron to synthesize its oxygen transport proteins in particular, 3 
hemoglobin and myoglobin (Abbaspour, et al., 2014), iron deficiency often leads to anemia. Iron 4 
deficiency results from insufficient intake of iron from diet and poor utilization of iron from 5 
ingested food or a combination of both factors (Gaucheron, 2000). The only proven way to lessen 6 
this issue is to increase iron intake, either by providing medicinal iron (supplementation) or by 7 
adding iron into the diet (fortification), basically to food staples (such as wheat and maize flour) 8 
or condiments (such as soy sauce, fish sauce, sugar and salt)(Cook & Reusser, 1983). Both these 9 
approaches heavily utilize ferrous based products (Patil, et al., 2012). In spite of the development 10 
of newer oral iron preparations, ferrous sulphate still remains the first line of treatment (Martı́nez-11 
Navarrete, et al., 2002) mainly due to its low cost and high availability (Patil, et al., 2012). 12 
However, the ferrous ion based supplements are not always compliant due to adverse 13 
gastrointestinal effects such as nausea, vomiting and gastric distress (Saha, et al., 2007), hence 14 
limiting the benefits of the iron supplementation therapy. In addition, some severe conditions may 15 
occur, such as allergic reactions, black and tarry stools, fever and continuing stomach pain (Hosny, 16 
et al., 2015). Further, its variability is very high in iron absorption, thus effecting the bioavailability 17 
(Bregman , et al., 2013 ). 18 
Therefore, there is a need for developing a novel, stable system which is able to increase the iron 19 
bioavailability. Previous work on encapsulation techniques for the treatment of anemia with nano 20 
drug delivery systems reports the use of ferrous sulphate loaded solid lipid nanoparticles (Zariwala, 21 
et al., 2013), (Hosny, et al., 2015). The prevention of exposure of ferrous directly to the 22 
gastrointestinal tract and the slow release property would be advantageous during its oral uptake. 23 
Furthermore, the need for high doses of iron to obtain the therapeutic effect can be avoided through 24 
slow release, minimizing the side effects associated with conventional oral iron supplements.  25 
Encapsulation protects ferrous ions interacting with other materials and prevents the direct contact 26 
of ferrous with gastrointestinal lumen, thus reducing the possible adverse effects (Hosny, et al., 27 
2015), (Xia & Xu, 2005). Alginate biopolymer system has promising properties (Sosnik 2014) and 28 
is safe to be used as an oral carrier for iron. Alginic acid and sodium alginate have turned out to 29 
be the most extensively explored mucoadhesive biomaterial with good cytocompatibility and 30 
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biocompatibility (Lee & Mooney, 2012) (Sarei, et al., 2013). One major advantage of using 31 
alginate in oral delivery formulations is their property of being in solid like structure at gastric 32 
conditions due to the formation of alginic acid. Hence, it protects the encapsulant inside the core 33 
(Draget & Taylor, 2011). Also, alginate beads dissolve under neutral and basic pH values which 34 
is more effective in iron delivery since the absorption of iron occurs mainly in the duodenum in 35 
which the pH is around 7.0-8.5 (Draget & Taylor, 2011).  36 
In the current study, we have examined the potential of alginate nanoparticles for oral iron delivery. 37 
The aim of our study was to formulate alginate nanoparticles to encapsulate ferrous sulphate and 38 
evaluate the release kinetics of iron in pH varying buffer solutions with a view to examining its 39 
potential as a nano-biopolymeric carrier of Fe2+. 40 
2. Materials and Methods 41 
2.1 Materials 42 
Low viscosity sodium alginate, ferrous sulphate, calcium chloride, Sorbitan monooleate (span 80) 43 
and L-ascorbic acid were purchased from Sigma-Aldrich Chemical Company (St. Louis, MO, 44 
USA). All other reagents were of analytical grade and used directly. Snake skin dialysis tubing 45 
(MWCO 3500) was purchased from Thermo Scientific USA. 46 
2.2 Preparation of ferrous loaded alginate nanoparticles 47 
The nanoparticles were prepared by ionic gelation based on methods described previously (Daemi 48 
& Barikani, 2012). The pH of a 0.3% w/v solution of sodium alginate (40.0 mL) was adjusted to 49 
around 5 and then stirred with span 80 for 2 h at 60 oC to obtain a homogeneous mixture. This 50 
sodium alginate solution was stirred with 50.0 mL of ferrous sulphate solution in the presence of 51 
ascorbic acid where the ratio of ferrous sulphate to ascorbic acid was always 15:1 and with varying 52 
iron concentrations (1%, 2% and 3%, w/w alginate). The above complex was gelated by drop wise 53 
addition of 40.0 mL of CaCl2 solution (0.1% w/v) while stirring at a high speed for 1 h. The 54 
nanoparticle suspension was refrigerated overnight and centrifuged at 9000 rpm for 45 minutes to 55 
obtain the nanoparticle pellet. 56 
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2.3 Characterization of ferrous loaded alginate nanoparticles 57 
2.3.1 particle size and zeta potential measurements 58 
 59 
The average particle size and size polydispersity of the nanoparticles dispersed in distilled water 60 
were determined by dynamic light scattering technique at 25 oC using a particle size analyzer 61 
(Zetasizer Nano ZS, Malvern Instruments, UK) at a fixed scattering angle of 90o. The zeta potential 62 
of nanoparticles was measured using the Zeta potential analyzer (Zetasizer Nano ZS, Malvern 63 
Instruments, UK). All measurements were performed in triplicate. 64 
2.3.2 Fourier Transform Infrared spectroscopy (FTIR) characterization and thermal analysis   65 
FTIR spectra of sodium alginate, alginate nanoparticles and iron loaded alginate nanoparticles 66 
were obtained with a Bruker Vertex 80 IR spectrometer (Germany) at a resolution of 4 cm-1 from 67 
4000 to 400 cm-1. Thermal decomposition of sodium alginate, alginate nanoparticles and ferrous 68 
loaded alginate nanoparticles were analyzed using a SDT Q600 thermogravimetric analyzer (TA 69 
Instruments, USA) from 25 oC to 800 oC using a ramp rate of 10 oC/ min in air. 70 
2.3.3 Transmission Electron Microscopic (TEM) imaging    71 
A drop of ferrous loaded alginate nanoparticle dispersion was placed on a holey carbon Cu grid 72 
and allowed to dry at room temperature. Then nanoparticles were imaged using a high resolution 73 
transmission electron microscope (TEM) (JEM 2100, JEOL, Japan) operated at accelerating 74 
voltage 200 kV.  75 
2.3.4 Electron energy loss spectroscopy (EELS) study of ferrous loaded nanoparticles 76 
EELS spectrum of ferrous loaded alginate nanoparticles was acquired with an EELS spectrometer 77 
(EELS Gatan, Quantum 963, USA) attached to the TEM with the energy resolution of 0.05 78 
eV/channel in STEM spectral imaging mode.  EELS spectra of FeCl3 and FeSO4 standards were 79 
acquired for a comparison study.  80 
2.4 Determination of encapsulation efficiency 81 
The amount of incorporated ferrous in the nanoparticles was determined by thiocyanate 82 
colorimetry. The supernatant obtained after centrifugation was subjected to oxidation with 0.15 83 
mol dm-3 of KMnO4 in acidic medium to convert all ferrous ions to ferric ions since ferrous ion 84 
does not form a coloured complex with thiocyanate. Next, the oxidized supernatant was complexed 85 
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with 1 mol dm-3 potassium thiocyanate solution and the absorbance was measured at 490 nm using 86 
the UV-Visible spectrophotometer (SHIMADZU, UV-3600, UV-VIS-NIR). Then, the 87 
concentration was calculated from a calibration plot obtained for ferric ion standard solution. 88 
Percentage encapsulation efficiency was calculated as follows. 89 
 90 
 91 
% Encapsulation efficiency =                                                         x 100%       Eq. 1 92 
 93 
2.5 In vitro release study of iron loaded alginate nanoparticles 94 
The release characteristics of iron from alginate nanoparticles were studied in pH 7.4, 6 and 2 95 
solutions. The iron loaded alginate nanoparticles were dispersed in 5.00 mL of buffer solution and 96 
trapped inside a dialysis membrane and this was immersed in 25.00 mL of buffer solution at 37 oC 97 
with mild agitation. Aliquots (3.00 mL) were withdrawn at predetermined time intervals and after 98 
the oxidation process with 0.15 mol dm-3 of KMnO4 in acidic medium, it was complexed with 1 99 
mol dm-3 potassium thiocyanate solution and then the UV absorbance at 490 nm was recorded 100 
using the UV-Visible spectrophotometer (SHIMADZU, UV-3600, UV-VIS-NIR). The release 101 
medium was refreshed with another 3.00 mL of medium after each withdrawal. All measurements 102 
were performed in triplicate. Using the calibration plot the concentrations were calculated hence 103 
the cumulative release percentages were determined.  104 
 105 
Release profiles obtained for different pH buffer solutions were fitted to 5 different mathematical 106 
models used to determine the kinetics of drug release from delivery systems: Zero order, First 107 
order, Higuchi, Hixon-Crowell and Korsemeyer-Peppas. The model that exhibited the adjusted R-108 
square closest to unity was selected as the best fit. The functions of the models considered are 109 
given below (Singhvi & Singh, 2011)(Lokhandwala, et al., 2013). 110 
 111 
Zero order Model 112 
𝑄𝑡 =  𝑄𝑂 +  𝐾𝑂 𝑡                                                                Eq. 2 113 
Where; 114 
Amount total 
Amount total – Amount supernatant 
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𝑄𝑡 −  amount of drug dissolved in time t 115 
𝑄𝑂 −  initial amount of drug in solution 116 
𝐾𝑂  - zero order release constant 117 
 118 
First order Model 119 
𝑙𝑜𝑔 𝐶𝑡 =  log 𝐶𝑂 − 𝑘𝑡/2.303                                            Eq. 3 120 
Where; 121 
 𝐶𝑡 - concentration of drug at time t 122 
CO-initial concentration of drug 123 
𝑘 – first order rate constant 124 
 125 
Higuchi Model 126 
𝑄𝑡 =  𝑘𝐻𝑡
1/2                                                                     Eq. 4 127 
Where; 128 
𝑄𝑡 – amount of drug released in time t 129 
𝑘𝐻 – Higuchi dissolution constant 130 
𝑡   - time 131 
 132 
Hixon-Crowell Model 133 
𝑊𝑂 
1/3 - 𝑊𝑡
1/3 = 𝑘𝑡                                                            Eq. 5 134 
Where; 135 
𝑊𝑂 - initial amount of drug in the pharmaceutical dosage form 136 
𝑊𝑡 - remaining amount of drug at time t 137 
𝑘   - constant incorporating surface-volume relation 138 
 139 
Korsmeyer-Peppas model 140 
Where; 141 
𝑀𝑡 / 𝑀∞ = 𝐾𝑡
𝑛                                                             Eq. 6 142 
𝑀𝑡 / 𝑀∞ - fraction of drug released at time t 143 
𝐾   - release rate constant 144 
𝑛   - release exponent 145 
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3. Results and Discussion 146 
 147 
3.1 Formation of ferrous loaded alginate nanoparticles 148 
The ionic gelation method was followed to synthesize the ferrous loaded alginate nanocomposite 149 
where calcium chloride was used as the cross linker. The preparation included two steps, i.e., 150 
droplet formation and droplet solidification. Ferrous chelated alginate droplets formation was 151 
achieved by the stirring with span 80 surfactant and then each droplet was solidified by ionic cross 152 
linking with calcium ions (Keawchaoon & Yoksan, 2011). The negative charge of sodium alginate 153 
is the driving force for complexation of ferrous with the polymer where chelation occurs between 154 
the Fe2+ with carboxylate and hydroxyl moieties. Around pH 5, the negatively charged carboxylate 155 
groups of alginate polymer are electrostatically linked with calcium ions. Since pKa value of 156 
alginate lies between 3.4 to 4.4 (Goswami, et al., 2014), the alginate biopolymer will be present as 157 
dissociated carboxylate ions around pH 5 facilitating the efficient crosslinking with calcium ions. 158 
Ascorbic acid was used as an antioxidant to protect the ferrous ion against oxidation.  159 
A preliminary experiment was carried out to optimise the iron content in the alginate nanoparticles. 160 
Thus formulations were prepared with varying iron concentrations (1%, 2% and 3%, w/w alginate) 161 
and iron encapsulation efficiencies were determined. The %encapsulation efficiencies were 75%, 162 
48% and 30% with the iron concentrations 1%, 2% and 3% w/w alginate respectively. Increased 163 
iron concentration correlated with a decreased amount of encapsulated iron. The higher ionic 164 
strength of ferrous sulphate being a strong electrolyte in water may have an influence in 165 
encapsulation with alginate (Xia & Xu, 2005).Thus, the highest encapsulation efficiency (75%), 166 
and hence the optimal concentration, was obtained with the formulation where the iron 167 
concentration was 1%, w/w with alginate. 168 
3.2 Successful loading of ferrous into alginate nanoparticles 169 
Changes in the FTIR spectrum of alginate nanoparticles on loading with ferrous sulphate indicate 170 
successful loading. The spectra of unloaded alginate nanoparticles and ferrous loaded alginate 171 
nanoparticles are shown in figure 1. The analysis of spectra indicates the presence of ferrous in 172 
alginate nanoparticles.  173 
The –OH stretching of hydroxyl of alginate nanoparticles (3340 cm-1) had shifted to 3350 cm-1 in 174 
the spectrum of ferrous loaded alginate nanoparticles. The position of carboxylate stretching peaks 175 
had also changed upon ferrous loading: the asymmetric –COO- stretching vibration at 1580 cm-1 176 
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of the native alginate nanoparticles had shifted to 1597 cm-1 in the spectrum of ferrous loaded 177 
alginate nanoparticles. The foregoing indicated the binding of Fe2+ with OH and COO- moieties. 178 
  179 
To further evaluate Fe2+ loading onto alginate nanoparticles (Fig. 2), thermo gravimetric analysis 180 
(TGA) was carried out (Fig. 2). In the unloaded alginate nanoparticles, TGA showed that 181 
degradation had occurred in four steps whereas with ferrous loaded alginate nanoparticles had an 182 
additional decomposition step from 110-180 oC due to the decomposition of ascorbic acid. 183 
Specifically, the 30% weight loss at 273 oC (the inflection point temperature) is followed by a 25% 184 
weight loss at 539 oC in the unloaded alginate nanoparticles. However, in the ferrous loaded 185 
particles the same weight loss is observed at 267 oC and 556 oC due to the interaction of ferrous 186 
with COO-/OH groups of the alginate. The residual weight of 8% with unloaded alginate 187 
nanoparticles might be due to the ash content and the formation of metal oxides.  The increased 188 
residual weight (20%) with ferrous loaded alginate nanoparticles is due to the formation of 189 
additional oxides of ferrous. Therefore, all the above reflect the successful loading of ferrous into 190 
alginate nanoparticles.  191 
To determine the elemental composition, in particular the loading of ferrous, and not ferric, into 192 
alginate nanoparticles, EELS technique was used. Fe core loss peak for L3 and L2 edges observed 193 
from EELS represent the excitation of Fe 2p3/2and 2p1/2 electrons (Egerton, 2009). An ionization 194 
edge appears at slightly different positions depending on the actual electron structure of a given 195 
material (Muller, et al., 1998). This difference in the onset position, also referred to as the chemical 196 
shift, in most cases does not exceed 1eV (Potapov & Schryvers, 2004). The EELS spectrum 197 
obtained for ferrous loaded alginate nanoparticles prepared in the presence of ascorbic acid clearly 198 
showed the characteristic L3 edge peak for Fe
2+ with a peak maximum at ~ 714.2 eV which is 199 
asymmetric with a slight shoulder on the high energy side (Aken & Liebscher, 2002). This edge 200 
structure is very similar to the L3 edge structure of Fe
2+ acquired for FeSO4 reference standard 201 
which has a peak maximum around 714 eV (Fig.3).While this L3 edge peak has a shifted peak 202 
maximum when it is compared with the L3 edge structure obtained for the reference standard 203 
(FeSO4), it is at a different position from FeCl3 with the peak maximum at 713.2 eV (Fig. 3). Thus, 204 
around 1 eV energy shift could be observed with L3 edge peaks of different oxidation states of 205 
iron. Therefore, these results confirm the loading of ferrous into alginate nanoparticles without 206 
oxidation to the ferric state.  207 
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 208 
3.3 Physiochemical properties of ferrous loaded nanoparticles 209 
Table 1: Shape, size and surface charge of ferrous loaded alginate nanoparticles where the iron 210 
concentration is 1%, w/w alginate. 211 
System 
Average Size/ 
nm 
Zeta potential/ 
mV 
% Encapsulation 
Efficiency 
Alginate nanoparticles 25 ± 9 -36 ± 3  
Ferrous loaded alginate 
nanoparticles 
20 ± 6 -38 ± 4 95 ± 4 
    
The particle morphology was examined through the TEM and is depicted in Fig.4. The spherical 212 
shape and smooth surfaces of the nanoparticles with no observed aggregation was clearly visible. 213 
Dynamic light scattering (DLS) technique was also used to determine the particle size distribution 214 
using Zetasizer Nano ZS. The average size of alginate nanoparticles was around 25 ± 9 nm (Table 215 
1), indicating their suitability as a delivery system for iron, for smaller nanoparticles are  better for 216 
solubility and bioavailability. 217 
 218 
The average zeta potential or the surface charge of the alginate nanoparticles was -36 ± 3 mV and 219 
the zeta potential of the ferrous loaded alginate nanoparticles was -38 ± 4 mV. Both values were 220 
quite similar. Considering the high surface to volume ratio of the nanoparticles, the negative charge 221 
is maintained even after the loading of iron. Another favorable point is that due to the potential of 222 
the particles they are sufficiently repelled from each other thus avoiding agglomeration.  223 
3.5 In vitro release studies of ferrous from alginate nanoparticles 224 
The in vitro release study of ferrous from ferrous loaded alginate nanoparticles was carried out in 225 
different pH media to confirm the ferrous encapsulation, to understand the release mechanism and 226 
kinetics and to determine the optimum condition (pH of medium) for releasing ferrous from the 227 
nanoparticles. The in vitro release profile of ferrous from the alginate nanocomposite in different 228 
pH buffer solutions (pH 7.4, 6 and 2) are shown in Figure 5. At pH 7.4 and 6, comparable release 229 
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profiles could be observed. As expected, an initial burst release of ferrous from alginate 230 
nanoparticles in both buffer solutions (pH 7.4 and 6) can be observed during 7-8 h, accounting for 231 
about 25-30% of ferrous from the total encapsulated amount. The initial burst release of ferrous 232 
may be due to the rapid hydration of nanoparticles considering the hydrophilic nature of alginate. 233 
Then, it followed a more gradual and sustained release phase for the next 78 h. The total amount 234 
of ferrous released from alginate nanoparticles at pH 7.4 buffer solution was around 65% after 96 235 
h while it was around 70% at pH 6. The release profile obtained at pH 2 was quite different from 236 
those obtained at pH 7.4 and 6. Here, the initial release was low and after 96 h the total release 237 
was less than 20%. Higher percentage of ferrous release at pH 7.4 and 6 is a very favorable 238 
condition for iron absorption since iron absorption predominantly occurs in the duodenum where 239 
the pH is around 6.     240 
Drug release kinetic studies were carried out using model dependent methods which describes the 241 
drug dissolution profiles and the best model fitting the release behavior of ferrous from alginate 242 
nanoparticles at different pH solutions was selected. According to their adjusted R2 values (Table 243 
2), the drug release from mucoadhesive alginate nanoparticles in all three different buffer solutions 244 
followed the zero order model for the burst release phase during the first 8 h. Thus, it explains the 245 
drug dissolution having similar initial release patterns at the pH values tested.  246 
Both Higuchi and Korsmeyer-Peppas models fit with the release behavior of the sustained release 247 
phase in all three buffer solutions during later 96 h with high R2 values. Higuchi model describes 248 
the drug release as liquid penetration followed by drug diffusion into the exterior solution 249 
depending on the concentration gradient (Singhvi & Singh, 2011). But Higuchi equation is not 250 
directly applicable to complex systems such as polymer matrices loaded with drugs which could 251 
be subjected to swelling and eroding (Grassi, et al., 2011) whereas Korsmeyer-Peppas model 252 
proposed a semi-empirical model in which the drug release is proportional to the sum of two 253 
different powers of time which account for the pure diffusivity contribution (Grassi, et al., 254 
2011)(Korsmeyer, et al., 1983). Hence, Korsmeyer-Peppas model best fit with these release studies 255 
at pH 7.4, 6 and 2 with high R2 values: 0.9659, 0.9457 and 0.9613 respectively. Further, the 256 
sustained release at pH 7.4 and 6 can be suggested as non-Fickian anomalous diffusion processes 257 
with the critical value of n being 0.5 and 0.45 respectively. While, the release behavior at pH 2 (n 258 
= 0.35) can be best described as a Fickian diffusion in which the release was mainly caused by 259 
diffusion only. For spherical particles, n ≤ 0.43 indicates a Fickian diffusion, while 0.43 < n < 260 
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0.85, indicate a non-Fickian release, an anomalous behavior corresponding to polymer hydration, 261 
solvent penetration, drug dissolution and polymer erosion which determine the drug release from 262 
hydrophilic polymer materials (Keawchaoon & Yoksan, 2011), (Motwani, et al., 2008) 263 
 264 
Table 2: Adjusted R2 values of curve fitting for five different drug release models obtained for the 265 
in vitro ferrous release from ferrous loaded alginate nanoparticles at different pH buffer solutions.  266 
 267 
Model R2 value for burst release phase R2 value for sustained release phase 
pH 7.4 pH 6 pH 2 pH 7.4 pH 6 pH 2 
Zero order 0.9960 0.9356 0.9600 0.8965 0.9946 0.9215 
First Order 0.9754 0.9189 0.9700 0.9491 0.9447 0.9485 
Higuchi 0.9725 0.8848 0.9824 0.9594 0.9615 0.9661 
Hixson-
Crowell 
0.9968 0.91176 0.9533 0.9356 0.9768 0.9205 
Korsmeyer-
Peppas 
0.9877 0.9078 0.9972 0.9659 0.9457 0.9613 
 268 
Release of 65-70% ferrous in the intestinal pH of 6 and 7.4 is good for oral delivery formulations. 269 
According to Goswami et al, the release of insulin from alginate nanoparticles at pH 1.2 was less 270 
than 20% while it was 90% at pH 7.4 because at low gastric pH alginate forms a compact acid-gel 271 
structure restricting the release of drug from the matrix and also protecting the drug from harsh 272 
environmental conditions (Goswami, et al., 2014). Another important factor is that the pKa of 273 
alginate lies well above 3.4, hence in very highly acidic medium, alginate remains undissociated 274 
protecting the encapsulated drug. Further, it is known that the gastric juice medium does not 275 
breakdown alginate nanoparticles thus providing the stability to the nanoparticles which makes 276 
them a suitable carrier in oral formulations (Goswami, et al., 2014). This claim is supported by our 277 
observations. Further, the mucoadhesive nanoparticles have the ability to penetrate mucous layer 278 
and prolong the residence time and released encapsulant can interact deeply and permeate the 279 
intestinal barrier to the bloodstream. This claim was supported by the work done by Sarmento et 280 
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al., on insulin loaded dextran sulphate/chitosan nanoparticles. They have observed the 281 
hypoglycemic effect for more than 24 h suggesting the insulin internalization, probably through 282 
vesicular structures in enterocytes and insulin-loaded nanoparticle uptake through intestine 283 
(Sarmento, et al., 2007). Smaller Particle size is also a necessity to be orally absorbed through the 284 
intestinal mucosa followed by their passage to systemic circulation (Reis, et al., 2007).  In our 285 
study, we were able to prepare alginate nanoparticles with sizes around 20-25 nm which may 286 
ensure the particle uptake through the intestine. This claim is further supported by the finding of 287 
Jani and co-workers who did a study on nanoparticle uptake by the rat gastrointestinal mucosa 288 
using different sized particles. They have shown the successful uptake of particles less than 50 nm 289 
by small intestine (Jani, et al., 1990). This ensures the improved bioavailability with minimized 290 
adverse effects of ferrous loaded alginate nanoparticles. 291 
 292 
4. Conclusion  293 
We demonstrate, the preparation of ferrous loaded alginate nanoparticles and its potential as a 294 
promising system for oral iron delivery. Alginate nanoparticle preparation was optimized for the 295 
initial iron content and the optimized formulation in which the iron concentration was 1%, w/w 296 
alginate, yielded nanoparticles in the size range of 15-30 nm with a negative surface charge and 297 
good iron encapsulation (75%). FTIR and TGA studies proved the successful loading of iron into 298 
the alginate nanoparticles while the EELS study confirmed the loading of ferrous in the presence 299 
of ascorbic acid. 70% release of ferrous at pH 6 and less than 20% release at pH 2 are favourable 300 
findings for further development of this as an oral iron delivery system. Ferrous loaded alginate 301 
nanoparticles thus provide an attractive delivery system for conventional oral iron therapy. 302 
 303 
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